Rethinking Partnerships In Cell & Gene Therapy—How MaxCyte's Business Model Drives Real Results

Navigating the complexities of cell and gene therapy (CGT) development requires more than just advanced technology; it demands strategic partnerships. In a recent Q&A, Sean Menarguez, Senior Director of Business Development at MaxCyte, sheds light on how MaxCyte's unique partnership model is accelerating progress and mitigating risks for CGT developers. He explains that MaxCyte goes beyond being a technology provider, offering a comprehensive framework that includes scalability, global regulatory support, and on-site technical expertise.

Discover how their Strategic Platform License (SPL) provides financially aligned access to these critical resources, empowering developers from early concepts through commercialization and helping them avoid common pitfalls in the journey to market.